ZhouQYinWDuYLuJ. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS One. 2014;9(1):e83646.
2.
RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684.
3.
GianniLDafniUGelberRD. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;(3):236–244.
4.
YinWJiangYShenZShaoZLuJTrastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6(6):e21030.
5.
VasiliadisIKolovouGMikhailidisDP. Cardiotoxicity and cancer therapy. Angiology. 2014;65(5):369–371.
6.
DiricanALeventFAlacaciogluA. Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation with oxidative stress. Angiology. 2014;65(10):944–949.
7.
KyBPuttMSawayaH. Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809–816.
8.
EschenhagenTForceTEwerMS. Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2011;13(1):1–10.
9.
JonesALBarlowMBarrett-LeePJ. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom national cancer research institute recommendations for monitoring. Br J Cancer. 2009;100(5):684–692.
10.
CarverJRShapiroCLNgA. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008.
